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Cost effectiveness analysis of a randomised trial of acupuncture
for chronic headache in primary care
David Wonderling, Andrew J Vickers, Richard Grieve, Rob McCarney
Abstract
Objective To evaluate the cost effectiveness of acupuncture in
the management of chronic headache.
Design Cost effectiveness analysis of a randomised controlled
trial.
Setting General practices in England and Wales.
Participants 401 patients with chronic headache,
predominantly migraine.
Interventions Patients were randomly allocated to receive up to
12 acupuncture treatments over three months from
appropriately trained physiotherapists, or to usual care alone.
Main outcome measure Incremental cost per quality adjusted
life year (QALY) gained.
Results Total costs during the one year period of the study
were on average higher for the acupuncture group (£403; $768;
€598) than for controls (£217) because of the acupuncture
practitioners’ costs. The mean health gain from acupuncture
during the one year of the trial was 0.021 quality adjusted life
years (QALYs), leading to a base case estimate of £9180 per
QALY gained. This result was robust to sensitivity analysis. Cost
per QALY dropped substantially when the analysis
incorporated likely QALY differences for the years after the
trial.
Conclusions Acupuncture for chronic headache improves
health related quality of life at a small additional cost; it is
relatively cost effective compared with a number of other
interventions provided by the NHS.
Introduction
Migraine and chronic tension headache represent a consider-
able societal burden in terms of both costs to the health service—
for example, for prescription drugs and visits to general
practitioners—and also the costs of lost productivity because of
reduced effectiveness and time off work.1–4 We have not found
recent estimates of the total economic burden of migraine for
the United Kingdom. A decade ago the annual costs to the
health service were estimated to be between £23m1 and £30m.2
Since these studies were published health service costs have
probably increased, given the prescription of more expensive
drugs (such as the triptans). The relatively modest observed costs
to the health service are often attributed to low consultation
rates, poor recognition of disease, and underprescribing.3 A
much greater burden is the cost to the economy of lost produc-
tivity: in the early 1990s this was estimated to be between £250m2
and £611m4 annually.
Public and scientific interest is increasing in acupuncture as
an approach for chronic headache disorders. Although several
randomised studies have been conducted,5 few reliable data are
available on the cost effectiveness of this intervention. We
present a cost effectiveness analysis carried out alongside a ran-
domised trial that seeks to assess the value for money of
acupuncture for chronic headache (ISRCTN96537534).
Methods
In the trial 401 patients aged 18-65 who reported an average of
at least two headaches per month were recruited from general
practices in England and Wales and randomly allocated to
receive either up to 12 acupuncture treatments over three
months from appropriately trained physiotherapists or usual
care alone.6
For the purposes of this evaluation we assume that the
acupuncture intervention to be provided in the community by
the NHS; hence wemeasure costs from both an NHS perspective
and a societal perspective. We measured effectiveness in terms of
the quality adjusted life years (QALYs) gained. For our base case,
we have taken a conservative approach by excluding savings in
productivity costs and by adopting a time horizon of 12 months,
the length of the trial follow up. Given the time horizon, no need
arose to discount costs or effects. We measured costs in UK
prices (£) for 2002-3. We used the algorithm devised by Brazier
et al,7 a single index measure of health related quality of life
(HRQoL)—the SF-6D—to calculate for each patient at baseline,
three months, and 12 months from patients’ responses to the
SF-36 at each of these time points.
The patients themselves reported unit costs associated with
non-prescription drugs and private healthcare visits.We used the
health component of the harmonised index of consumer prices
to inflate these costs to 2003 levels.8 Table 1 details other unit
costs. We used standard NHS costs for a specific service if these
had been published.9 For NHS visits to practitioners of comple-
mentary or alternative medicine we used the mean cost of a pri-
vate visit, as recorded in the trial.We recorded drug prescriptions
for a subgroup of patients (n = 71) from the database of their
general practitioner.
To estimate the cost of the study intervention we took the
standard cost (including overheads, capital, and training) for an
NHS community physiotherapist9 and multiplied it by the
contact time for each individual patient with the physiotherapist
trained in acupuncture. We did not include the cost of needles
and other consumables as these are negligible compared with
staff time.13 We assumed that acupuncture sessions on the NHS,
but not by a study acupuncturist, had a duration equal to the
mean duration of a study session, 31 minutes.
We used using linear regression (analysis of covariance,
ANCOVA) with age, sex, diagnosis (migraine or non-migraine
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headache), severity of headache at baseline, number of years of
headache disorder, site, and baseline SF-6D as covariates to esti-
mate differences between groups for cost and effectiveness on
the intention to treat principle. Exact methods for estimating
confidence intervals for incremental cost effectiveness ratios are
not possible, and we therefore used the net benefit approach to
estimate parametric cost effectiveness acceptability curves.14 15
Net benefit analysis usually requires any gain in outcome (for
example, QALYs) from an intervention to be valued by using the
ceiling ratio, , defined as the decision makers’ willingness to pay
for an additional unit of health outcome, and from this any addi-
tional costs are subtracted. A  equal to £30 000 per QALY is a
threshold of cost effectiveness consistent with decisions that have
been taken by the National Institute for Clinical Excellence
(NICE).16 The cost effectiveness acceptability curves show the
probability that the incremental cost effectiveness is below , for
a range of values of .We used SPSS for Windows, version 11.0.0,
to perform statistical analysis and Microsoft Excel 2002 SP2 for
the calculation of cost effectiveness acceptability curves.
For the base case we conducted no imputation for cases
missing HRQoL data; therefore the cost effectiveness analysis
sample was those patients who reported SF-36 completely in all
three questionnaires and for whom QALYs could therefore be
calculated. Data on use of resources and cost were available for a
larger sample of cases, and for these variables we report statistics
for all responding patients.
Economic evaluation is subject to uncertainty not just
because of sample variation but also because of assumptions
made and generalisability issues.17 We therefore conducted sensi-
tivity analyses to test the robustness of the results to changes in
the base case assumptions. We varied the staff time and grade
associated with acupuncture treatment and used different
strategies for missing data. We also added productivity costs by
multiplying the number of days sick from work or other usual
activity, as reported by the study patients, by the average earnings
per day in England and Wales11 inflated to 2003 prices.12 The
base case analysis does not project beyond the 12 months of
observation. It is improbable that the difference in HRQoL
observed at 12 months would disappear immediately. In the sen-
sitivity analysis we assumed that, although the study acupuncture
intervention was delivered as a one off package and not taken up
again in subsequent years, the difference in costs (excluding acu-
puncture) and effectiveness would gradually subside at the same
rate over varying periods of time. We discounted costs at 6% and
QALYs at 1.5%, in keeping with the conventions of UK central
government.18
Results
Table 2 shows the baseline characteristics for the patients who
completed the SF-36 on all three occasions. This group forms
our sample for our base case analysis of cost effectiveness. Tables
3 and 4 show resource use, HRQoL, and cost; for these tables we
report the results from all responding individuals.
Patients in the acupuncture arm had on average 4.2 hours of
contact with a study acupuncturist (table 3). Two patients in the
control arm were treated by one of the study acupuncturists, and
18 patients in the acupuncture arm did not attend for acupunc-
ture. Some patients (30 in the acupuncture arm and two in the
control arm) visited an acupuncturist for further acupuncture
(either NHS or private). Hence the cost of the study acupuncture
sessions was augmented by the cost of additional acupuncture
sessions (table 4).
We found small but statistically significant reductions in
expenditure on visits to general practitioners and complemen-
tary or alternative medications (table 4). Differences in other cost
components did not reach significance. We obtained costs for
prescription drugs from a subsample of 71 patients, and we had
hoped to extrapolate results from these patients to the full study
sample. However, regression models of these costs had poor
properties: linear regression was heteroscedastic, and results dif-
fered depending on the various alternative regression methods
used. We therefore excluded costs for prescription drug costs
Table 1 Unit costs
Cost component Unit cost (£) Source of unit cost Details*
Acupuncture
Study acupuncture
visit (per hour)
43.00 Netten and Curtis
20029
Clinic visit to
community
physiotherapist
Non-study NHS
acupuncture visit
22.28 Netten and Curtis
20029; trial data
£0.72×31minutes
Private acupuncture
visit
Various Trial data Patients reported
individual costs
NHS visits
General practitioner 27.00 Netten and Curtis
20029
Cost per clinic
consultation
Outpatient 82.00 Netten and Curtis
20029
Generic cost per
outpatient attendance
Counsellor or
psychotherapist
35.75 Netten and Curtis
20029
Clinic visit to
community based
counsellor
Physiotherapy 17.00 Netten and Curtis
20029
Clinic visit to
community
physiotherapist
Chiropractor or
osteopath
25.38 Trial data Mean cost of a private
visit
Medical herbalist 18.17 Trial data Mean cost of a private
visit
Homoeopath 31.46 Trial data Mean cost of a private
visit
Hypnotherapist 38.75 Trial data Mean cost of a private
visit
Relaxation therapy 6.92 Trial data Mean cost of a private
visit
Other costs (base
case)
Private health care
visits
Various Trial data Patients reported
individual costs
Over the counter
medication
Various Trial data Patients reported
individual costs
Other costs
(sensitivity
analysis)
General practitioner
cost per hour
118.00 Netten and Curtis
20029
Cost per hour of
patient contact
Private acupuncture 28.38 Trial data Mean cost of a private
visit
Prescription drugs Various BNF September 200210 Specified by dosage
and pack size.
Cost of a day off sick 88.05 Office for National
Statistics11
Average earnings per
hour×average working
hours = £11.7411×7.512
*All NHS visit costs include salary, on-costs, qualifications, overheads, and capital overheads.
Table 2 Characteristics of patients for whom QALYs could be calculated
(sample size: acupuncture=136, control=119)
Acupuncture arm Control arm
Mean age in years (SD) 46.7 (9.7) 46.0 (11.0)
No of female participants (%) 111 (82%) 102 (85%)
Mean chronicity in years (SD) 22.1 (14.8) 21.8 (13.3)
Mean headache severity score at baseline (SD)* 24.1 (14.0) 27.0 (16.9)
No of participants with migraine (%) 128 (94%) 113 (95%)
SD=standard deviation
*Patients completed a 6 point Likert scale (0-5) four times a day for four weeks. The score is
the weekly average.6
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from the cost effectiveness analyses. As differences between
groups were small ( < £50 per patient) and tended to favour the
acupuncture group, exclusion of the costs of prescription drugs
is a conservative measure that is unlikely to have an important
influence on cost effectiveness estimates.
Table 3 reports HRQoL as measured by the SF-6D.We noted
an improvement in QALYs over the 12 months in the acupunc-
ture group but not in controls, with the difference between
groups reaching significance (P = 0.02). We estimated the mean
health gain to be 0.021 QALYs, equivalent to eight quality
adjusted days (table 5).
We estimated the mean incremental cost of the acupuncture
intervention to the NHS to be £205 per patient, excluding the
impact on prescription drugs (table 5). This was offset slightly by
a small reduction in direct patient costs (over the counter medi-
cation and visits to practitioners of complementary and alterna-
tive medicine).Overall this equates to an additional cost of £9180
per QALY gained, including patient costs.
Figures 1 and 2 show the probability that the intervention is
cost effective (under our base case assumptions) for a range of cost
effectiveness ceilings. At a ceiling of £30 000 per QALY gained (a
threshold of cost effectiveness consistent with decisions that have
been taken by NICE16). the probability that acupuncture is cost
effective is 92%. The figures also show how cost effectiveness
changes for several different scenarios (details and further
scenarios in table 6). Given the relative value of a general
practitioner’s time, acupuncture by physiotherapists represents
better value for money. Even if a general practitioner can manage
to treat four patients in an hour this is still less cost effective than a
physiotherapist treating two per hour (the base case scenario).
We saw a marked improvement in cost effectiveness
associated with the inclusion of productivity costs. However, this
represents an underestimate of the cost per QALY since the
quality of life measure will in part reflect this improved produc-
tivity, especially with respect to increased leisure time. Estimated
Table 3 Use of resources and health related quality of life
Resource
Acupuncture arm Control arm
Mean (SD) n Mean (SD) n
No of acupuncture visits
Acupuncture, study 7.92 (3.76) 205 0.10 (1.03) 196
Study hours of contact 4.24 (2.31) 205 0.06 (0.59) 196
Acupuncture, other NHS 0.79 (2.31) 177 0.01 (0.08) 157
Acupuncture, private 0.34 (1.45) 177 0.01 (0.16) 157
No of other healthcare visits
General practitioner 1.72 (2.54) 177 2.65 (3.79) 157
Outpatient 0.26 (0.93) 177 0.15 (0.65) 157
Other, NHS 0.10 (0.64) 177 0.27 (1.57) 157
Other, private 2.77 (8.70) 177 2.71 (7.52) 157
Health related quality of life (SF-6D, score out of
100)
Baseline 69.3 (13.2) 197 70.6 (12.8) 189
At 3 months 71.2 (13.6) 157 70.3 (13.1) 143
At 12 months 73.9 (14.3) 150 70.7 (13.3) 133
n=sample size; SD=standard deviation.
Table 4 Costs in £
Cost
Acupuncture arm Control arm
Difference* Mean (95% CI)Mean (SD) n Mean (SD) n
Acupuncture
Acupuncture, study 201.49 (89.62) 177 3.02 (28.60) 157 198.97 (185.72 to 212.22)
Acupuncture, other NHS 17.54 (51.55) 177 0.14 (1.78) 157 17.76 (9.65 to 25.86)
Acupuncture, private 10.68 (46.27) 177 0.38 (4.79) 157 10.48 (3.08 to 17.89)
Other healthcare visits
General practitioner 46.40 (68.48) 177 71.67 (102.34) 157 −21.38 (−39.89 to −2.87)
Outpatient 21.68 (76.49) 177 12.10 (53.32) 157 10.24 (−4.15 to 24.63)
Other, NHS 2.59 (18.80) 177 6.63 (39.61) 157 −3.48 (−9.59 to 2.63)
Other, private 73.15 (262.04) 177 68.38 (369.97) 157 −5.00 (−62.61 to 52.61)
Medication
Over the counter drugs 39.07 (60.97) 177 39.42 (50.67) 157 0.00 (−11.87 to 11.87)
Complementary or alternative
medication
1.72 (10.00) 177 5.68 (17.82) 157 −4.01 (−7.13 to −0.88)
Prescription drugs† 160.98 (365.77) 36 211.51 (484.15) 35 −32.04 (−231.27 to 167.18)
n=sample size; SD=standard deviation; CI=confidence interval.
*Adjusted for baseline variables.
†Subsample only.
Table 5 Cost effectiveness. Values are means (standard deviations) unless
otherwise indicated
Acupuncture arm
n=136
Control arm
n=119
Mean difference‡
(95% CI)
NHS cost (£)* 289.65 (165.86) 88.65 (130.28) 205.34 (169.33 to 241.35)
Patient cost (£) 113.75 (258.24) 128.56 (426.56) −15.91 (−86.24 to 54.42)
Total cost (£)† 403.40 (356.69) 217.20 (486.00) 189.42 (102.24 to 276.61)
Quality adjusted life
years (QALYs)
0.727 (0.119) 0.708 (0.112) 0.021 (0.001 to 0.040)
Incremental cost per QALY gained: £9951 (NHS cost); £9180 (total cost).
*Excluding prescription drug costs.
†Total cost (£)=NHS cost+patient cost.
‡Adjusted for baseline variables.
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cost effectiveness was also improved by the projection of effects
beyond one year and the assumption that acupuncturists could
improve their throughput by dealing with patients simultane-
ously. Cost effectiveness was not markedly different when we
used private acupuncture costs. Similarly, imputing values for
cases with missing data did not greatly influence the results,
although the explanatory power of the imputation regressions
was weak. Under none of the scenarios did the central estimate of
cost indicate overall cost savings.
Discussion
Acupuncture lead to increases in both QALYs and health service
costs. We estimated the incremental cost effectiveness to be
£9180 per QALY gained. The estimated improvement in quality
of life correlates with the observed reductions in headache sever-
ity and frequency.
We consider that the base case is likely to be conservative as it
excludes cost savings associated with prescription drugs and
productivity gains. More importantly, our base case analysis con-
siders only the 12 months of the trial. The effects of acupuncture
appear to be persistent as differences between groups were
slightly larger at one year than immediately post-treatment. If we
include likely QALY differences for subsequent years, then acu-
puncture appears even better value for money.
Acupuncture by medical general practitioners (as well as by
specialist physiotherapists) appears to be reasonably cost
effective compared with usual care, however, given the relative
value of a general practitioner’s time, acupuncture by
physiotherapists represents better value for money, unless
general practitioners can achieve substantially better outcomes
and or much shorter contact times.
The probability that the programme is cost effective at a ceil-
ing of £30 000 was estimated to be 92% for the base case. This
does not take into account the uncertainty owing to imputing
missing values, which means that this probability is a slight over-
estimate. When only complete responders are included in the
analysis the probability falls to 84%, but this estimate is biased
conservatively. This study, like most economic evaluations,19 was
not powered to detect a difference in cost effectiveness and
therefore the lack of statistical significance at the 5% level should
not be interpreted as evidence of non-cost effectiveness—few if
any economic evaluations attain such levels of significance.
Table 6 Sensitivity analyses
Sample size Incremental cost (£) QALYs gained
Incremental cost per QALY
gained (£)
Base case (see table 5) 255 189.42 0.021 9180
Alternative unit costs associated with
acupuncture*
Using average cost of a private acupuncture
session
255 234.72 0.021 11375
Physiotherapist can treat three patients per hour 255 117.64 0.021 5701
General practitioner instead of physiotherapist
(treating four patients per hour)
255 254.50 0.021 12333
Strategy for handling of missing values
Include only patients completing all cost
questionnaires
220 201.52 0.018 11474
Imputation of QALYs and cost† 401 164.59 0.015 10836
Inclusion of additional cost component
Productivity costs (days off sick) 255 67.34 0.021 3263
Projection of results into the future
Trial arms converge by 2 years 255 183.33 0.039 4730
Trial arms converge by 5 years 255 166.39 0.092 1807
Trial arms converge by 10 years 255 142.10 0.177 801
All analyses adjust for baseline variables.
*Assumes same health outcome as the base case.
†Using linear regression to predict missing values from baseline parameters.
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To our knowledge, this is the first rigorous economic evalua-
tion of acupuncture. Prior economic studies on acupuncture for
pain have typically been conducted by acupuncture advocates
and have used questionable methods. For example, studies have
claimed cost savings on the basis of hypothetical interventions
that would have been necessary had acupuncture not been
administered.13 20 Other studies have used before-after compari-
sons21 or non-randomised controls.22 Cost savings have been
shown by retrospective studies of acupuncture for other
conditions, but similar methodological problems have been
described.23
Our study, with a relatively large sample size, a randomised
comparison arm, and prospective evaluation of costs, has not
found such overall cost savings for headache patients: we can be
fairly certain from our results that acupuncture adds to health
service costs for these patients. Therefore the pertinent question
is whether this additional cost is justified by the associated health
gains. Even when we use our conservative base case estimate of
£9180 per QALY gained, acupuncture for migraine seems to be
better value for money than several interventions that have been
recommended by NICE.16 To our knowledge, a cost per QALY
analysis has only been performed for one other antimigraine
intervention—sumatriptan compared with oral caffeine and
ergotamine—which had a cost per QALY of $C29 366
(£16 000).24 Acupuncture therefore compares favourably.
Clinicians, commissioners, and patients should consider acu-
puncture for migraine and chronic headache as it seems to
reduce the severity of headache and improves HRQoL at a small
additional cost. It is an intervention that is relatively cost effective
compared with a number of interventions provided by the NHS.
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What is already known on this topic
Acupuncture is widely used for chronic pain
A number of small trials, and recently a larger more
rigorous trial, indicate that acupuncture is of benefit for
chronic headache disorders
No rigorous cost effectiveness assessments of acupuncture
have been previously undertaken
What this study adds
Acupuncture improves health related quality of life
(HRQoL), but increases costs to the health service
Cost effectiveness was estimated to be £9180 per QALY
gained, or less if analysis incorporated likely QALY
differences for the years after the trial
If decision makers are willing to pay up to £30 000 to gain
one QALY then acupuncture in the treatment of chronic
headache is highly likely to be cost effective
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